mitoxantrone has been researched along with Leukemia, Myelomonocytic, Juvenile in 1 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Leukemia, Myelomonocytic, Juvenile: A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, SA | 1 |
| Coulter, DW | 1 |
| Grovas, AC | 1 |
| Gordon, BG | 1 |
| Harper, JL | 1 |
| Warkentin, PI | 1 |
| Wisecarver, JL | 1 |
| Sanger, WG | 1 |
| Coccia, PF | 1 |
1 other study available for mitoxantrone and Leukemia, Myelomonocytic, Juvenile
| Article | Year |
|---|---|
Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Dis | 2014 |